It is a very heterogeneous disease and may be divided into several major subcategories, including hormone-receptor (HR)-positive (HR+; ER+, PR+/−, and HER2−), HER2-positive (HER2+), and triple-negative (TN; ER−, PR−, and HER2−) breast cancer [3]. This evidence concerns the gene HR and breast carcinoma.